Dual specificity phosphatase 6 suppresses the growth and metastasis of prostate cancer cells

Zhai,Xiaolei; Han,Qianhe; Shan,Zhongjie; Qu,Xiaowei; Guo,Liang; Zhou,Yudong

doi:10.3892/mmr.2014.2575

Dual specificity phosphatase 6 suppresses the growth and metastasis of prostate cancer cells

Authors:
- Xiaolei Zhai
- Qianhe Han
- Zhongjie Shan
- Xiaowei Qu
- Liang Guo
- Yudong Zhou
View Affiliations

Affiliations: Department of Urology, People's Hospital of Zhengzhou, Zhengzhou, Henan 450003, P.R. China
Published online on: September 18, 2014 https://doi.org/10.3892/mmr.2014.2575
Pages: 3052-3058

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dual specificity phosphatase 6 (DUSP6) is expressed at low levels in numerous types of human cancer. The loss of DUSP6 plays a pivotal role in tumor progression; however, the role of DUSP6 in prostate cancer remains unclear. In this study, in vitro invasion assays and in vivo metastasis experiments were used to investigate the effects of DUSP6 on prostate cancer cell invasion and metastasis. Furthermore, in vitro growth and soft agar assays and in vivo growth experiments were performed to determine the function of DUSP6 in cell proliferation. The results showed that the overexpression of DUSP6 suppressed the invasion and growth of DU‑145 human prostate cancer cells, whereas knockdown of DUSP6 promoted the invasion and proliferation of LNCap human prostate adenocarcinoma cells. Further experiments demonstrated that the overexpression of DUSP6 inhibited the proliferation and liver metastasis of DU‑145 cells in mice. In addition, DUSP6 downregulated the expression of matrix metallopeptidase 3 and interleukin 8 in prostate cancer cells. Taken together, these findings indicate that DUSP6 may act as a negative mediator in the regulation of prostate cancer cell growth and metastasis.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
2	Steeg PS: Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 12:895–904. 2006. View Article : Google Scholar : PubMed/NCBI
3	Martin GS: Cell signaling and cancer. Cancer Cell. 4:167–174. 2003. View Article : Google Scholar
4	Theodosiou A and Ashworth A: MAP kinase phosphatases. Genome Biol. 3:30092002. View Article : Google Scholar
5	Okudela K, Yazawa T, Woo T, et al: Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis. Am J Pathol. 175:867–881. 2009. View Article : Google Scholar : PubMed/NCBI
6	Furukawa T, Fujisaki R, Yoshida Y, et al: Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod Pathol. 18:1034–1042. 2005. View Article : Google Scholar
7	Chan DW, Liu VW, Tsao GS, et al: Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis. 29:1742–1750. 2008. View Article : Google Scholar : PubMed/NCBI
8	Wong VC, Chen H, Ko JM, et al: Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype. Int J Cancer. 130:83–95. 2012. View Article : Google Scholar : PubMed/NCBI
9	Li W, Song L, Ritchie AM and Melton DW: Increased levels of DUSP6 phosphatase stimulate tumourigenesis in a molecularly distinct melanoma subtype. Pigment Cell Melanoma Res. 25:188–199. 2012. View Article : Google Scholar : PubMed/NCBI
10	Zhang YY, Wu JW and Wang ZX: Mitogen-activated protein kinase (MAPK) phosphatase 3-mediated cross-talk between MAPKs ERK2 and p38alpha. J Biol Chem. 286:16150–16162. 2011. View Article : Google Scholar : PubMed/NCBI
11	Lee JU, Huang S, Lee MH, et al: Dual specificity phosphatase 6 as a predictor of invasiveness in papillary thyroid cancer. Eur J Endocrinol. 167:93–101. 2012. View Article : Google Scholar
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
13	Yang JL, Lin JH, Weng SW, et al: Crude extract of Euphorbia formosana inhibits the migration and invasion of DU145 human prostate cancer cells: The role of matrix metalloproteinase-2/9 inhibition via the MAPK signaling pathway. Mol Med Rep. 7:1403–1408. 2013.
14	Lehrer S, Diamond EJ, Mamkine B, Stone NN and Stock RG: Serum interleukin-8 is elevated in men with prostate cancer and bone metastases. Technol Cancer Res Treat. 3:4112004. View Article : Google Scholar : PubMed/NCBI
15	Huang S, Pettaway CA, Uehara H, Bucana CD and Fidler IJ: Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion and metastasis. Oncogene. 20:4188–4197. 2001. View Article : Google Scholar : PubMed/NCBI
16	Owens DM and Keyse SM: Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene. 26:3203–3213. 2007. View Article : Google Scholar : PubMed/NCBI
17	Keyse SM: Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 27:253–261. 2008. View Article : Google Scholar : PubMed/NCBI
18	Arnoldussen YJ and Saatcioglu F: Dual specificity phosphatases in prostate cancer. Mol Cell Endocrinol. 309:1–7. 2009. View Article : Google Scholar : PubMed/NCBI
19	Xu S, Furukawa T, Kanai N, Sunamura M and Horii A: Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J Hum Genet. 50:159–167. 2005. View Article : Google Scholar : PubMed/NCBI
20	Furukawa T, Yatsuoka T, Youssef EM, et al: Genomic analysis of DUSP6, a dual specificity MAP kinase phosphatase, in pancreatic cancer. Cytogenet Cell Genet. 82:156–159. 1998. View Article : Google Scholar : PubMed/NCBI
21	Skrzypski M, Dziadziuszko R, Jassem E, et al: Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes. Clin Lung Cancer. 14:666–673. 2013. View Article : Google Scholar : PubMed/NCBI
22	Piya S, Kim JY, Bae J, Seol DW, Moon AR and Kim TH: DUSP6 is a novel transcriptional target of p53 and regulates p53-mediated apoptosis by modulating expression levels of Bcl-2 family proteins. FEBS Lett. 586:4233–4240. 2012. View Article : Google Scholar : PubMed/NCBI
23	Lee H, Kim JM, Huang SM, et al: Differential expression of DUSP6 with expression of ERK and Ki-67 in non-small cell lung carcinoma. Pathol Res Pract. 207:428–432. 2011. View Article : Google Scholar : PubMed/NCBI
24	Furukawa T, Sunamura M, Motoi F, Matsuno S and Horii A: Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol. 162:1807–1815. 2003. View Article : Google Scholar : PubMed/NCBI
25	Lim BJ, Jung SS, Choi SY and Lee CS: Expression of metastasis-associated molecules in non-small cell lung cancer and their prognostic significance. Mol Med Rep. 3:43–49. 2010.PubMed/NCBI
26	Jin X, Yagi M, Akiyama N, et al: Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer Sci. 97:1327–1334. 2006. View Article : Google Scholar : PubMed/NCBI
27	Liu HQ, Song S, Wang JH and Zhang SL: Expression of MMP-3 and TIMP-3 in gastric cancer tissue and its clinical significance. Oncol Lett. 2:1319–1322. 2011.PubMed/NCBI
28	Chen Y, Shi M, Yu GZ, et al: Interleukin-8, a promising predictor for prognosis of pancreatic cancer. World J Gastroenterol. 18:1123–1129. 2012. View Article : Google Scholar : PubMed/NCBI
29	Waugh DJ and Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
30	Xie K: Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 12:375–391. 2001. View Article : Google Scholar
31	Inoue K, Slaton JW, Eve BY, et al: Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res. 6:2104–2119. 2000.PubMed/NCBI
32	Lee LF, Louie MC, Desai SJ, et al: Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene. 23:2197–2205. 2004. View Article : Google Scholar